Hong Kong To Review, Improve Drug-Regulation System
This article was originally published in PharmAsia News
Hong Kong authorities are exploring improvements in the region's pharmaceutical system, particularly in existing regulations. Hong Kong's secretary for Food and Health told the Legislative Council that as a result of recent incidents involving pharmaceuticals, his agency and the Department of Health and Hospital Authority plan comprehensive steps to improve the system. Among regulations to be reviewed is the Good Manufacturing Practices requirement. The plan is to introduce risk-assessment principles and conduct microbiology testing. (Click here for more
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.